the first-line maintenance setting via Early Access Programmes (Italy, UK), Temporary Use Authorization (France) or reimbursement following regulatory approval (Italy, UK). Main study endpoint is real-world PFS. Secondary endpoints include overall survival and response rate. The study will also describe surrogate measures of response and tolerability, including time to discontinuation, dose modifications (with reasons) and time to first and second subsequent treatment. Outcomes will be described by key subgroup status pre-index, including performance status, FIGO stage, BRCA status, debulking surgery outcome and clinical response to chemotherapy. The study aims to include 350 patients. Retrospective data collection began in December 2020 and is planned to end by Q3 2023. As of April 2021, 69 patients have participated.

**UPLIFT (ENGOT-OV67/GOG-3048) A PIVOTAL COHORT OF UPFITAMAB RILSODOTIN, A NAPl2B-DIRECTED ADC IN PLATINUM-RESISTANT OVARIAN CANCER**

1. N Concin*, 2,3 E Hamilton, 4 L Randall, 5 S Baneeje, 6 M Mileshkin, 7 Rl Coleman, 8,9,10,11 B Monk, 12,13,14,15,16,17 MR Mirza, 18 A Savarese, 19 R Ray-Coquard, 20,21,22,23 A Perez Fidalgo, 24 P Bernard, 25 E Putti, 26 R Burger, 27 R Mosher, 28 D Richardson, 29 D Cibula, 30 R Madhy, 31 R Chekera, 32 T Van Gorp, 33 Medical University of Innsbruck, Austria; Department of Obstetrics and Gynaecology, Innsbruck, Austria; 34 Sarah Cannon Research Institute, Nashville, United States; 35 Tennessee Oncology, Nashville, United States; 36 VCU Health System, MCV Physicians, Department of Obstetrics and Gynecology Oncology, Richmond, United States; 37 The Royal Marsden NHS Trust, Institute of Cancer Research, London, United Kingdom; 38 Peter MacCallum Cancer Centre, Melbourne, Australia; 39 Texas Oncology-The Woodlands, The Woodlands, United States; 40 GOG Foundation; 41 Arizona Oncology; 42 US Oncology Network, Phoenix, United States; 43 US Oncology, Gynecologic Program; 44 GOG Partners; 45 Rigshospitalet, Copenhagen, Denmark; 46 Nordic Society of Gynecological Oncology, Clinical Trial Unit, Denmark; 47 European Network of Gynecologic Tumor Groups; 48 Gynecologic Cancer Int-Group; 49 European Society of Medical Oncology; 50 European Society of Gynecological Oncology; 51 Regina Elena National Cancer Institute, Rome, Italy; 52 Leon Bérard Center, Lyon, France; 53 Hospital Clinic Universitari, Valencia, Spain; 54 Mersana Therapeutics Inc, Cambridge, United States; 55 OH Health Stephenson Cancer Center, Oklahoma City, United States; 56 Charles University, Czech Republic; 57 Poznan University of Medical Sciences, Poznan, Poland; 58 Charte – Universitätsmedizin Berlin, Berlin, Germany; 59 Uz Leuven, oncology, Leuven, Belgium

10.1136/ijgc-2021-ESGO.351

Introduction/Background* Upfitamab rilsodotin (XMT-1536; UpRi), is a first-in-class Dolaflexin antibody-drug conjugate targeting NaPi2b, a sodium-dependent phosphate transport protein broadly expressed in solid tumors including high-grade serous epithelial ovarian cancer (OC). UpRi’s safety and efficacy are being evaluated in a Phase I study (NCT03319628). Preliminary antitumor activity from an expansion cohort of heavily-pretreated OC patients has been reported (Hamilton et al, ESMO 2020). A data-cut of December 2020 demonstrated an ORR of 39% including 2 CRs and DCR of 81% in 26 OC patients with high NaPi2b expression (TPS ≥75). The 2 patients achieving CR had previously been treated with bevacizumab and PARPi (Richardson et al, ASCO 2021, TPS5607). The prevalence of a TPS ≥75 is greater than 60%.

PROC remains a serious unmet medical need as available treatment options provide modest benefit of no more than 12% ORR and median OS less than 12 months. Based on encouraging anti-tumor activity of UpRi, UPLIFT was designed as a Phase 2 single-arm registration strategy for PROC as part of the ongoing study.

Methodology The UPLIFT cohort is enrolling patients with platinum resistant high grade serous ovarian, fallopian tube and primary peritoneal cancer with up to 4 prior lines of therapy. Prior bevacizumab is required for patients with 1 or 2 prior lines of therapy but is not required for patients with 3-4 prior lines of therapy. UPLIFT will enroll approximately 180 patients globally for 100 patients with high NaPi2b expression. UpRi is dosed intravenously at 43 mg/m2 every 4 weeks. Patients may enroll regardless of NaPi2b expression and regardless of baseline peripheral neuropathy. Baseline tumor samples (fresh or archived) will be collected for retrospective tumor tissue evaluation of NaPi2b expression.

Result(s)* The primary objective is assessment of objective response rate in patients with high NaPi2b expression. The cut-off for high NaPi2b expression is TPS ≥75 and was based on data from the expansion cohort. Secondary endpoints include objective response rate in the overall population, duration of response, and adverse events.

Conclusion* This study is being conducted in collaboration with ENGOT and GOG. Patients will be enrolled globally. (NCT03319628).

**SURGICAL OUTCOME AS PROGNOSTIC FACTOR IN DIFFERENT HISTOLOGIC SUBTYPES OF OVARIAN CARCINOMA: ANALYSIS OF 7 PHASE III TRIALS BY AGO STUDYGROUP + ENGOT**

1-2 Heitz*, 1-2 A Du Bois, 2,3,4 Reul, 5-6 Pujade-Lauraine, 7 MR Mirza, 7 Greggi, 7 N Colombo, 8 C Marth, 9 B Vergote, 10 P Harter, 11 R Ray-Coquard, 12 GB Kirstensen, 13 MG Mahner, 14 AC Hardy, 15 J Sehouli, 16 K Winther, 17 K Eichbaum, 18 G Elser, 19 W Meier, 20,21 Pfister. Kliniken Essen-Mitte, Gynecology and Gynecologic Oncology; 22 AGO Study Group, Wiesbaden; 23 Philipps University Marburg, Coordinating Center for Clinical Trials of the Philipps-University of Marburg, Marburg, Germany; 24 GINECO and Hôpital Dieu, Paris, France; 25 NSGO & Rigshospitalet, Dept. of Oncology, Copenhagen University Hospital, Copenhagen; 26 Mito & Istituto Nazionale per lo Studio e la Curita dei Tumori di Napoli, Gynecologic Oncology, Naples, Italy; 27 MaNGO & European Institute of Oncology, Gynecologic Oncology, Milano, Italy; 28 AGO-A & Innsbruck Medical University, Department of Obstetrics and Gynecology, Innsbruck; 29 BG UOG & University Hospitals Leuven, Dept. of Gynecologic Oncology, Leuven, Belgium; 30 GINECO & Centre Leon Bérard Université Claude Bernard Lyon Est, Lyon; France; 31 NSGO & Oslo University Hospital, Oslo, Norway; 32 University Hospital, LMU Munich, Department of Obstetrics and Gynecology, 33 GINECO & Hôpital Privé des Côtes d’Armor, Pléneuf; 34 NOGGO & Charité -Universitätsmedizin Berlin, Campus Virchow, Dpt. Gynecology with Center for Oncological Surgery, Berlin, Germany; 35 University Hospital Essen and University Hospital Carl Gustav Carus, Tu Dresden, Department of Gynecology and Obstetrics, Dresden; 36 Helios Dr. Horst Schmidt Kliniken Wiesbaden, Department of Gynecology, Wiesbaden; 37 Düsseldorf University Hospital and Evangelisches Krankenhaus Düsseldorf, Department of Gynecology and Obstetrics, Düsseldorf, Germany; 38 Gynecologic Oncology Center, Kiel, Germany

10.1136/ijgc-2021-ESGO.352

Introduction/Background* Debulking surgery is the mainstay of treatment for patients (pts) with advanced epithelial ovarian cancer (EOC). Upfront surgery (PDS) with complete macroscopic resection (TR0) is associated with best survival while PDS to small residual disease (TR1-10) provides moderate benefit in high grade serous OC. The impact of resection status in other histological subtypes so far has not been defined and especially the role of TR1-10 is under debate. This analysis should help to better understand the interplay between histological subtype, surgical outcome, and prognosis.

Methodology Data of patients (>FIGO IIIB) from 7 AGO-Studygroup led phase III multicentre trials (AGO-OVAR 3, 5,7,9,11,12,15), (1995–2011) were pooled and analysed with focus on PDS resection status on overall survival (OS) in different histological subtypes: low grade (low grade serous or endometrioid), mucinous, clear cell, and high-grade (e.g.)